SCHEMBL24310648

SCHEMBL24310648

Cn1cc(S(=O)(=O)Nc2nc(Cl)c(C(F)(F)F)c(Oc3ccc(Cl)cc3)n2)cn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 1/20 0.37
▸ AURKB Q96GD4 1/20 0.37
▸ LMNA P02545 5/20 0.37
▸ MAPT P10636 3/20 0.37
▸ POLB P06746 2/20 0.37
▸ HTT P42858 2/20 0.37
▸ ALDH1A1 P00352 4/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ XBP1 P17861 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ GPR119 Q8TDV5 2/20 0.35
▸ EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566415 1.00 AURKA (0.37) AURKAAURKBLMNAMAPTPOLB
SCHEMBL24309367 0.89 CTSC (0.42) ALDH1A1EGFRBRD4
SCHEMBL29566620 0.89 CTSC (0.42) ALDH1A1EGFRBRD4
SCHEMBL29567013 0.87 PTK2 (0.35) LMNAMAPTPOLBHTTKMT2A
SCHEMBL24309771 0.87 PTK2 (0.35) LMNAMAPTPOLBHTTKMT2A
SCHEMBL24309646 0.85 HTR1A (0.37) LMNAMAPTPOLBHTTKMT2A
SCHEMBL29566971 0.85 HTR1A (0.37) LMNAMAPTPOLBHTTKMT2A
SCHEMBL26808422 0.84 KAT6A (0.39) HTTALDH1A1L3MBTL1SMN1; SMN2EGFR
SCHEMBL24309808 0.83 CTSC (0.46) EGFR
SCHEMBL29566696 0.83 CTSC (0.46) EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B AURKA 4683/4885AURKB 4115/4885LMNA 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback